Cognition Therapeutics logo

Cognition TherapeuticsNASDAQ: CGTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

08 October 2021

Next earnings report:

26 March 2025

Last dividends:

N/A

Next dividends:

N/A
$18.07 M
-92%vs. 3y high
23%vs. sector
-vs. 3y high
-vs. sector
-80%vs. 3y high
44%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | 88 min ago
$0.43-$0.02(-5.04%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

CGTX Latest News

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
globenewswire.com13 November 2024 Sentiment: POSITIVE

- CT1812 slowed cognitive decline by 95% in Alzheimer's disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD -

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD
globenewswire.com29 October 2024 Sentiment: POSITIVE

- Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer's disease pathology -

Analyses from Cognition's Positive Phase 2 ‘SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD
globenewswire.com23 October 2024 Sentiment: POSITIVE

Presenting prespecified analysis of cognitive impact on plasma p-Tau 217 subgroups in ‘SHINE' Poster Presentation details b aseline characteristics from the signal-finding ‘SHIMMER' trial in DLB PURCHASE, N.Y., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced Michael Woodward, MD, FRACP, head of dementia research at Austin Health in Melbourne, Australia, will deliver an oral presentation at the Clinical Trials on Alzheimer's Disease (CTAD) conference, which is taking place October 29 - November 1, 2024, in Madrid, Spain.

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference
globenewswire.com02 October 2024 Sentiment: POSITIVE

PURCHASE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs to treat neurodegenerative disorders, today announced the Company's president and CEO Lisa Ricciardi will participate in a panel discussion titled Frontiers in Neuroscience during the 3rd Annual Roth Healthcare Opportunities Conference on October 9, 2024.

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia
globenewswire.com01 October 2024 Sentiment: POSITIVE

Cognition is advancing CT1812 in the Phase 2 ‘SHIMMER' clinical trial for the treatment of dementia with Lewy bodies with data readout in the fourth quarter of 2024 Cognition is advancing CT1812 in the Phase 2 ‘SHIMMER' clinical trial for the treatment of dementia with Lewy bodies with data readout in the fourth quarter of 2024

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
globenewswire.com03 September 2024 Sentiment: POSITIVE

PURCHASE, N.Y., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced the Company's president and CEO, Lisa Ricciardi will participate in two investor conferences in September.

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease
globenewswire.com22 August 2024 Sentiment: POSITIVE

PURCHASE, N.Y., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that results from the SEQUEL study of CT1812, the Company's lead candidate for the treatment of Alzheimer's disease, were published in The Journal of Prevention of Alzheimer's Disease . SEQUEL was a single-site study that measured brain wave patterns in 16 adults with mild-to-moderate Alzheimer's disease following 29-days of treatment with CT1812 or placebo. In this study, CT1812-treated participants exhibited consistent trends of improvement across all prespecified electroencephalography (EEG) parameters with several reaching significance, including the change in relative theta power in the central region (p=0.006) of the brain and AEC-c* (p=0.034), which assesses the connectivity between brain regions.

Cognition Therapeutics, Inc. (CGTX) Q1 2024 Earnings Call Transcript
seekingalpha.com11 August 2024 Sentiment: NEUTRAL

Cognition Therapeutics, Inc. (NASDAQ:CGTX ) Q2 2024 Earnings Conference Call August 11, 2024 8:30 AM ET Company Participants Thomas Johnson - Director, Corporate Communications, LifeSci Advisors, LLC Lisa Ricciardi - Chief Executive Officer John Doyle - Chief Financial Officer Anthony Caggiano - Chief Medical Officer, Head of R&D Conference Call Participants Charles Duncan - Cantor Fitzgerald Raghuram Selvaraju - H.C. Wainwright Daniil Gataulin - Chardan Operator Hello, and thank you for standing by.

Cognition Therapeutics to Report Second Quarter 2024 Financial Results
globenewswire.com05 August 2024 Sentiment: NEUTRAL

- Conference Call and Live Audio Webcast Scheduled for August 8, 2024 - - Conference Call and Live Audio Webcast Scheduled for August 8, 2024 -

Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today?
investorplace.com29 July 2024 Sentiment: NEGATIVE

Cognition Therapeutics (NASDAQ: CGTX ) stock is falling hard on Monday after the clinical-stage biopharmaceutical company provided results from its proof-of-concept Phase 2 ‘SHINE' study. This study evaluated the effectiveness of treating patients with CT1812.

What type of business is Cognition Therapeutics?

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

What sector is Cognition Therapeutics in?

Cognition Therapeutics is in the Healthcare sector

What industry is Cognition Therapeutics in?

Cognition Therapeutics is in the Biotechnology industry

What country is Cognition Therapeutics from?

Cognition Therapeutics is headquartered in United States

When did Cognition Therapeutics go public?

Cognition Therapeutics initial public offering (IPO) was on 08 October 2021

What is Cognition Therapeutics website?

https://www.cogrx.com

Is Cognition Therapeutics in the S&P 500?

No, Cognition Therapeutics is not included in the S&P 500 index

Is Cognition Therapeutics in the NASDAQ 100?

No, Cognition Therapeutics is not included in the NASDAQ 100 index

Is Cognition Therapeutics in the Dow Jones?

No, Cognition Therapeutics is not included in the Dow Jones index

When was Cognition Therapeutics the previous earnings report?

No data

When does Cognition Therapeutics earnings report?

The next expected earnings date for Cognition Therapeutics is 26 March 2025